<DOC>
	<DOC>NCT01898156</DOC>
	<brief_summary>This Phase 1/2 study is designed to assess the following: safety and tolerability of BIW-8962, Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D) in Phase 1 in subjects with advanced/recurrent lung cancers or mesothelioma and preliminary efficacy in Phase 2 in subjects with advanced/recurrent Small Cell Lung Cancer.</brief_summary>
	<brief_title>Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>Phase 1: histopathologicaldocumented, measurable or nonmeasurable unresectable, advanced primary or recurrent SCLC, NSCLC or mesothelioma Phase 2: measurable, unresectable advanced or recurrent SCLC A life expectancy &gt; 3 months Eastern Cooperative Oncology Group (ECOG) performance status score of 01 at study entry Echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) ≥ 50%, or ≥ institution's established lower limit of normal Adequate hematologic, hepatic, renal and lung function Subject received cytotoxic anticancer chemotherapy, orally available signaling pathwaytargeted therapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 3 weeks prior to the first dose Subject received monoclonal antibodies within 4 weeks of the first dose Major surgery within 4 weeks prior to the first dose Known symptomatic brain metastases Clinically significant cardiovascular disease Leptomeningeal disease Uncontrolled intercurrent illness including ongoing or active infection, uncontrolled diabetes, etc Known HIV disease or acquired immunodeficiency syndromerelated illness A psychiatric illness, disability or social situation Hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins A history of primary brain/CNS malignancy Neurological paraneoplastic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>